Figure 1
From: PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma
Disease specific survival (DSS) of patients with p16 and human papillomavirus positive oropharyngeal squamous cell carcinoma. DSS was assessed only for patients with > 2 months of follow-up (n = 72). A. pT stage and disease specific survival. B. Clinical stage and disease specific survival. C. PIK3CA mutational status and disease specific survival. D. Presumed activation of PI3K pathway and disease specific survival. Cases with PI3K pathway activating alteration with < 2 months of follow-up were excluded from the DSS analysis.